Patents Represented by Attorney Frank S. Chow
  • Patent number: 6150532
    Abstract: The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganism, eukaryoic cells, whole animals and human being. R' and R" are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl. R'" is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, arylalkyl. X is aryl. Y is selected from hydrogen or ##STR1## wherein (*) indicates a potential point of attachment to X.
    Type: Grant
    Filed: December 11, 1998
    Date of Patent: November 21, 2000
    Inventors: Adnan Mjalli, Sepehr Sarshar, Xiaodong Cao, Farid Bakir
  • Patent number: 6107274
    Abstract: Compounds of formula A are disclosed: ##STR1## wherein R.sup.1 is aralkyl or cycloalkyl; R.sup.2 is cycloalkylmethyl, alkyl, or aralkyl;R.sup.3 is hydrogen, alkyl, substituted phenyl (including p-phenoxy-phenyl), or fluorene;R.sup.4 is hydrogen, alkyl, substituted phenyls (including 1-alkyl-4-carboxy-substituted phenyls), alkyl carboxylic acids;R.sup.5 is hydrogen or R.sup.1 and R.sup.5 taken together forming a tetrahydroisoquinoline ring or a piperidine ring.These compounds exhibit inhibitory action against fructose-1,6-bisphosphatase (FBPase) and are indicated in the treatment or management of Type II diabetes.
    Type: Grant
    Filed: March 15, 1999
    Date of Patent: August 22, 2000
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, James Christopher Mason, Kristen Lee Arienti, Kevin Michael Short, Rachel Denise Anne Kimmich, Todd Kevin Jones
  • Patent number: 5965558
    Abstract: Y--X--C(R').dbd.C(R")COOR"'(A1)The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryoic cells, whole animals and human beings. R' and R" are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl. R"' is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, arylalkyl. X is aryl. Y is selected from hydrogen or ##STR1## wherein (*) indicates a potential point of attachment to X.
    Type: Grant
    Filed: October 29, 1997
    Date of Patent: October 12, 1999
    Assignee: Ontogen Corporation
    Inventors: Adnan Mjalli, Sepehr Sarshar, Xiaodong Cao, Farid Bakir
  • Patent number: 5866569
    Abstract: There are disclosed methods useful for the inhibition of inducible nitric oxide synthase by the adminstration of a compound of the formula I:. when R.sub.2 is H then R.sub.1 is selected from the group consisting of:1) aryl,--NH--C.sub.0 -C.sub.10 alkyl -aryl, N-(C.sub.0 -C.sub.10 alkyl substituted aryl).sub.2, --C.sub.0 -C.sub.10 alkyl substituted aryl, --N(C.sub.0 -C.sub.10 alkyl substituted aryl)(C.sub.0 -C.sub.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: February 2, 1999
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Sepehar Sarshar, Chengzhi Zhang
  • Patent number: 5840721
    Abstract: The present invention relates to polysubsituted imidazole having formula 1 ##STR1## These compounds are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: November 24, 1998
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Chengzhi Zhang
  • Patent number: 5770620
    Abstract: The present invention provides novel protein tyrosine phosphatase modulating compounds having an aryl acrylic acid structure, compositions comprising the compounds, and methods of making and using the same.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: June 23, 1998
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Xiaodong Cao, Edmund J. Moran
  • Patent number: 5756527
    Abstract: The present invention relates to imidazole derivatives having formula 1 ##STR1## wherein: R.sub.1 is selected from the group consisting of: mono-,di-,and tri-substituted phenyl or thienyl, the substituents are selected from the group consisting of:(i) substituted C.sub.1-6 alkyl, substituted C.sub.2-6 alkyloxy, wherein the substituents are selected from the group consisting of hydrogen or C.sub.1-6 alkoxy;(ii) C.sub.1-11 CO.sub.2 R.sub.5, trans-CH.dbd.CHCO.sub.2 R.sub.5, wherein R.sub.5 is C.sub.1-11 alkyl, or phenyl C.sub.1-11 alkyl;R.sub.2 and R.sub.3 are mono-, di, and tri-substituted phenyl wherein the substituents are independently selected from:(i) halo;(ii) C.sub.1-6 alkyl-amino, or di(C.sub.1-6 alkyl)amino, and R.sub.4 is hydrogen.These compounds are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: May 26, 1998
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Sepehr Sarshar
  • Patent number: 5753687
    Abstract: Y--X--C(R').dbd.C(R")COOR'" (A1)The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryoic cells, whole animals and human beings. R' and R" are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl. R'" is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, arylalkyl. X is aryl. Y is selected from hydrogen or ##STR1## wherein (*) indicates a potential point of attachment to X.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: May 19, 1998
    Assignee: Ontogen Corporation
    Inventors: Adnan Mjalli, Sepehr Sarshar, Xiaodong Cao, Farid Bakir
  • Patent number: 5750595
    Abstract: There is disclosed a self-dispersing curable epoxy resin composition comprising the addition product of reactants comprising (a) 1.0 reactive equivalent of an epoxy resin, (b) from about 0.1 to 1.0. reactive equivalents of a polyhydric phenol, and (c) from about 0.005 to 0.5 reactive equivalents of an amine-epoxy adduct comprising the addition product of reactants comprising 1.0 reactive equivalent of a polyepoxide and from about 0.3 to 0.9 reactive equivalents of a compound having the structural formula:?R.sub.1 --O--!.sub.2-m --R.sub.2 --?--CH.sub.2 CH(R.sub.3)--X--R.sub.4 --NH.sub.2 !.sub.mwherein: R.sub.1 designates a monovalent organic radical selected from the group consisting of C.sub.1 to C.sub.12 aliphatic, alicyclic or aromatic hydrocarbons, and R.sub.2 represents a polyoxyalkylene chain having the structural formula:(CH.sub.2 --CH.sub.2 --O).sub.a --(CH.sub.2 --CH(R.sub.5)--O).sub.bwherein: R.sub.5 is a monovalent organic radical selected from the group consisting of C.sub.1 to C.sub.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 12, 1998
    Assignee: Henkel Corporation
    Inventors: Kartar S. Arora, Michael S. Wiggins
  • Patent number: 5726048
    Abstract: A mutant fungal strain, namely G. candidum NRRL Y-552, mutant known as Henkel 9-2-3-9 produces a lipase called "UNLipase" providing a selectivity of 25:1 for oleic acid over palmitic acid by the assay procedure employed. UNLipase has a temperature range of operation of between 0 and 40 degrees Celsius (and no activity over 55 degrees Celsius). The optimum pH ranges are between 7.5 and 8.5. Magnesium cations increase activity, whereas calcium cations are inhibitory. The molecular weight of the protein appears to be 65 kDa by size exclusion chromatography. UNLipase shows a high degree of selectivity for hydrolysis, esterification and transesterification.
    Type: Grant
    Filed: August 9, 1995
    Date of Patent: March 10, 1998
    Assignee: Henkel Corporation
    Inventors: Dean A. Oester, Allen L. Hall, Stephen J. Vesper
  • Patent number: 5723451
    Abstract: There are disclosed methods useful for the inhibition of inducible nitric oxide synthase by the adminstration of a compound of the Formula I: ##STR1## to a patient in need of such inhibition such as hypotension, inflammation, autoimmune diseases and septic shock and the like.
    Type: Grant
    Filed: August 9, 1996
    Date of Patent: March 3, 1998
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Sepehar Sarshar, Chengzhi Zhang
  • Patent number: 5700826
    Abstract: This invention relates to compounds of Formula 1 which are pharmacologically useful for the treatment of cancer through sensitization of multi-drug resistant cancer cells to chemotherapeutic agents. ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are, respectively hydrogen, alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, substituted aryl.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 23, 1997
    Assignee: Ontogen Corporation
    Inventors: Adnan Mjalli, Sepehr Sarshar
  • Patent number: 5672465
    Abstract: Described is a radiation sensitive imaging film containing a heat fixable radiation sensitive element, e.g., a diacetylene, of the formula: R--C.tbd.C--C.tbd.C--R', where R and R' are, e.g., both --CH.sub.2 --O--CONH--(CH.sub.2).sub.5 CH.sub.3. After exposure to X-radiation during diagnostic or X-ray therapy, the resulting image can be permanently dry fixed by a short heating step and then stored for a long period. Processes for making the film, new binder-convertor systems, and a device incorporating the film are described as well as other imaging, diagnostic and therapeutic methods utilizing the film in high energy radiation applications in the health care field.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: September 30, 1997
    Assignee: JP Laboratories, Inc.
    Inventors: Gordhanbhai N. Patel, Yao-Ming Cheng, Subhash H. Patel
  • Patent number: 5648409
    Abstract: There is disclosed a self-disbursing curable epoxy resin composition comprising the addition product of reactants comprising (a) 1.0 reactive equivalent of an epoxy resin, (b) from about 0.40 to 0.95 reactive equivalents of a polyhydric phenol, and (c) from about 0.005 to 0.5 reactive equivalents of an amine-epoxy adduct comprising the addition product of reactants comprising 1.0 reactive equivalent of an aromatic polyepoxide and from about 0.3 to 0.9 reactive equivalents of a polyoxyalkyleneamine.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: July 15, 1997
    Assignee: Henkel Corporation
    Inventors: Kartar S. Arora, David I. Devore, Reuben H. Grinstein, Grannis S. Johnson, John G. Papalos, Shailesh Shah
  • Patent number: 5646044
    Abstract: This invention discloses an expression system which is useful in industrial Bacilli to produce target proteins which include, but are not limited to, alkaline proteases, amylases, cellulases, lipases or other hydrolyases which are normally excreted outside of the host cell.
    Type: Grant
    Filed: March 2, 1995
    Date of Patent: July 8, 1997
    Assignee: Henkel Kommanditgesellschaft auf Aktien
    Inventors: Charles R. Wilson, Maria R. Tang, Harald Berger, Teresa M. Christianson, Dieter Hansen
  • Patent number: 5506333
    Abstract: A polyester is provided which facilitates the separation of blood into light and heavy phases via centrifugation in a blood collection vessel. The polyester is useful as a component of a partitioning composition formulated to have appropriate specific gravity to be positioned intermediate the light and heavy blood phases during centrifugation. A partitioning composition including a polyester of the invention provides a particular advantage in blood collection vessels due to its lighter and more consistent coloration. The polyester composition can be prepared with relative ease compared to prior art polyesters useful in blood partitioning compositions.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: April 9, 1996
    Assignee: Henkel Corporation
    Inventors: William L. O'Brien, Alan C. Kilbarger
  • Patent number: 5500364
    Abstract: Mutant B. lentus DSM 5483 proteases are derived by the replacement of at least one amino acid residue of the mature form of the B. lentus DSM 5483 alkaline protease. The mutant proteases are expressed by genes which are mutated by site-specific mutagenesis. The amino acid sites selected for replacement are identified by means of a computer based method which compares the three dimensional structure of the wild-type protease and a reference protease.
    Type: Grant
    Filed: June 2, 1994
    Date of Patent: March 19, 1996
    Assignee: Cognis, Inc.
    Inventors: Teresa Christianson, Dean Goddette, Beth F. Ladin, Maria R. Lau, Christian Paech, Robert B. Reynolds, Charles R. Wilson, Shiow-Shong Yang
  • Patent number: 5470741
    Abstract: A mutant fungal strain, namely G. candidum NRRL Y-552, mutant known as Henkel 9-2-3-9 (ATCC 74170) produces a lipase called "UNLipase" providing a selectivity of 25:1 for oleic acid over palmitic acid by the assay procedure employed. UNLipase has a temperature range of operation of between 0 and 40 degrees Celsius (and no activity over 55 degrees Celsius). The optimum pH ranges are between 7.5 and 8.5. Magnesium cations increase activity, whereas calcium cations are inhibitory. The molecular weight of the protein appears to be 65 kDa by size exclusion chromatography. UNLipase shows a high degree of selectivity for hydrolysis, esterification and transesterification.
    Type: Grant
    Filed: July 22, 1992
    Date of Patent: November 28, 1995
    Assignee: Henkel Corporation
    Inventors: Dean A. Oester, Allen L. Hall, Stephen J. Vesper
  • Patent number: 5453200
    Abstract: In a process for separating the exocellular proteins from the micro-organisms of a filtered fermentation liquor, the removal of solid is to be improved while retaining the useful substance. This is achieved by, in a first stage, removing substances preventing protein precipitation with the aid of a solid adsorption agent; concentrating the remaining solution to a protein content of about 30 to 40% by weight; and then precipitating and separating the protein, optionally with the addition of precipitants for protein to accelerate the precipitation, at pH values between 6 and 10.
    Type: Grant
    Filed: May 26, 1993
    Date of Patent: September 26, 1995
    Assignee: Henkel Kommanditgesellschaft auf Aktien
    Inventors: Albrecht Weiss, Wolfgang Berke
  • Patent number: D363300
    Type: Grant
    Filed: June 1, 1993
    Date of Patent: October 17, 1995
    Assignee: Caprock Developments, Inc.
    Inventor: Seymour Schwartz